<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004407</url>
  </required_header>
  <id_info>
    <org_study_id>199/13294</org_study_id>
    <secondary_id>MAYOC-91596</secondary_id>
    <secondary_id>MAYOC-FDR001358</secondary_id>
    <nct_id>NCT00004407</nct_id>
  </id_info>
  <brief_title>Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic Neuropathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine the effect of intravenous immunoglobulin on recovery time of&#xD;
      patients with proximal diabetic neuropathy.&#xD;
&#xD;
      II. Determine whether rate of response is dose dependent in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are&#xD;
      randomized to treatment with low dose intravenous immunoglobulin (IVIg), high dose IVIg, or&#xD;
      placebo.&#xD;
&#xD;
      Patients must first complete baseline evaluation. Patients receive IVIg or placebo on days 1,&#xD;
      2, 3, and 5, biweekly at weeks 2-4, weekly at weeks 5-8, and every other week at weeks 9-12.&#xD;
&#xD;
      Patients are assessed at 6, 12, 36, 52, and 104 weeks.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 1998</start_date>
  <completion_date>March 2000</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>75</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>immune globulin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Diagnostically proven non-insulin dependent diabetes mellitus as defined by the&#xD;
             following criteria: Presence of classic symptoms, such as polyuria, polydipsia,&#xD;
             ketonuria, and rapid weight loss, together with plasma glucose elevations Elevated&#xD;
             fasting glucose concentration on more than one occasion&#xD;
&#xD;
          -  Diagnostically proven proximal diabetic neuropathy with any of the following symptoms:&#xD;
             Severe thigh, hip, or leg pain Greater than 20% weight loss Progressive proximal&#xD;
             weakness in the painful leg Weakness in the contralateral lower limb Thoracic or&#xD;
             cervical root distribution Symmetric distal polyneuropathy or autonomic neuropathy may&#xD;
             be mild or absent&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  At least 6 months since prior immunosuppression or plasma exchange&#xD;
&#xD;
          -  No history of prior renal transplant&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Age: 18 and over&#xD;
&#xD;
          -  Performance status: Gait impairment at least grade 2&#xD;
&#xD;
          -  Hematopoietic: Not specified&#xD;
&#xD;
          -  Hepatic: Not specified&#xD;
&#xD;
          -  Renal: Creatinine no greater than 1.4 mg/dL (women) Creatinine no greater than 1.5&#xD;
             mg/dL (men) No history of renal failure&#xD;
&#xD;
          -  Cardiovascular: No history of cardiac failure&#xD;
&#xD;
          -  Neurologic: Normal nerve conduction studies or changes compatible with distal&#xD;
             symmetric diabetic neuropathy or diabetic lumbosacral radioplexus neuropathy Spinal&#xD;
             fluid cell count less than 5 cells/mm3 Normal cerebral spinal fluid cytology No&#xD;
             structural spine disease No inherited neuropathy&#xD;
&#xD;
          -  Other: Electromyographic evidence of proximal lower limb plexus OR Radicular&#xD;
             denervation compatible with proximal diabetic neuropathy No other systemic disease or&#xD;
             malignancy Normal IgA levels No chronic inflammatory demyelinating&#xD;
             polyradiculoneuropathy (CIDP) No systemic amyloidosis No monoclonal gammopathy&#xD;
             associated neuropathy No history of allergy to serum products No selective cervical or&#xD;
             root involvement without lower limb weakness No evidence of secondary diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony J. Windebank</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <verification_date>January 2001</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>diabetic amyotrophy</keyword>
  <keyword>diabetic lumbosacral radiculoplexus neuropathy</keyword>
  <keyword>diabetic neuropathy</keyword>
  <keyword>diabetic proximal neuropathy</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

